PR Newswire BiotechOriginal article
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
Data ReadoutpositivedarovasertibcrizotinibPositive
AI Analysis
Summary
IDEAYA Biosciences and Servier announced data from three clinical trials at ESMO 2026, including OptimUM-01 and OptimUM-02, supporting darovasertib plus crizotinib as a potential foundational therapy across the treatment journey in uveal melanoma. The data were described as encouraging irrespective of HLA-A*02:01 status or line of therapy.
Clinical Trial Data
Outcome Details
OptimUM-01 and OptimUM-02 data presented at ESMO 2026 support darovasertib plus crizotinib's potential to drive clinical benefit in metastatic uveal melanoma regardless of HLA-A*02:01 allele status or line of therapy; OptimUM-01 data described as encouraging.
Importance:6/10
Sentiment:
0.60
ESMO 2026uveal melanomadarovasertibcrizotinibOptimUM-01OptimUM-02oncologyclinical dataServier partnership
Related Companies
Read the original article
Published by PR Newswire Biotech on October 19, 2026 10:00 AM